Position in XENE
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$81,004,520
+$56,368,535 QoQ
Shares Held
1,393,027
+153.4% QoQ
Ownership
1.44%
of shares outstanding
% of Portfolio
5.73%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in XENE Over Time
Shares Held
Position Value (USD)
Derivatives in XENE
reported options exposure · as of Dec 31, 2025CallValue
$0
CallShares
0
PutValue
$24,637,554
PutShares
549,700
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Caligan Partners LP holds $1,086,520,401 across 21 Biotechnology names. XENE ranks #4 (7.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
1,461,924 | $162,785,237 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
1,652,808 | $160,735,578 | |
| 3 | PCVX |
Vaxcyte, Inc.
|
2,060,719 | $119,748,381 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
This page
|
1,393,027 | $81,004,520 | |
| 5 | MLYS |
Mineralys Therapeutics, Inc.
|
2,772,654 | $75,111,196 | |
| 6 | EXEL |
Exelixis, Inc.
|
1,553,262 | $66,619,407 | |
| 7 | TNGX |
Tango Therapeutics, Inc.
|
2,408,798 | $50,392,054 | |
| 8 | TYRA |
Tyra Biosciences, Inc.
|
1,276,968 | $48,907,874 |
All Filings in XENE
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $81,004,520 | 1,393,027 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $24,635,985 | 549,665 | Shares | Sole | 2026-02-17 | |
| 2025-12-31 | $24,637,554 | 549,700 | Put | Sole | 2026-02-17 | |
| 2025-09-30 | $17,849,284 | 444,565 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||